Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis

Código QR

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis

Guardado en:

Detalles Bibliográficos
Autores principales:	Annunziata Dattola, Arianna Zangrilli, Luca Bianchi
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	guttate psoriasis plaque psoriasis risankizumab renal disease Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/d93fdf443c4d465998bcb5b9c8ef624d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021)

Dermoscopy Differentiates Guttate Psoriasis From a Mimicker—Pityriasis Rosea
por: Meena Makhecha, et al.
Publicado: (2021)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy V, et al.
Publicado: (2020)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Yuliya Lytvyn, PhD, et al.
Publicado: (2022)

Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy
por: Abhijeet Kumar Jha, et al.
Publicado: (2018)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
por: Chang-Jin Jung, et al.
Publicado: (2021)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton P, et al.
Publicado: (2021)

Management of scalp psoriasis: current perspectives
por: Blakely K, et al.
Publicado: (2016)

Psoriasis
por: MOLL LEE,NORMAN
Publicado: (1947)

Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
por: Mahé E
Publicado: (2020)

Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016)

Psoriasis eritrodérmica y psoriasis artropática: Relate de dos casos
por: STEEGER,ADALBERTO, et al.
Publicado: (1956)

Diagnosis and screening of patients with generalized pustular psoriasis
por: Ly K, et al.
Publicado: (2019)

An Atypical Case of Pustular Psoriasis Presenting With Severe Subungual Abscesses Involving All Fingers
por: A. Tulin Mansur
Publicado: (2019)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon S, et al.
Publicado: (2017)

Updates on the Treatment of Erythrodermic Psoriasis
por: Lo Y, et al.
Publicado: (2021)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Aimilios Lallas, et al.
Publicado: (2016)

Effectiveness of Short-Term Physical Agents Treatment on Macroscopic Morphology in Patients with Plaque Psoriasis
por: Norambuena-Mardones,Leandra, et al.
Publicado: (2019)

The new external drug for the treatment of psoriasis based on inhibition of serine proteases
por: Alexander S. Zhukov, et al.
Publicado: (2021)

The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East
por: Steinhoff M, et al.
Publicado: (2020)

Psoriasis and alcohol
por: Svanström C, et al.
Publicado: (2019)

Psoriasis Pustular
por: ROSSELOT,JORGE
Publicado: (1951)

Psoriasis and uveitis: links and risks
por: Fotiadou C, et al.
Publicado: (2019)

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy
por: Agozzino M, et al.
Publicado: (2017)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck KM, et al.
Publicado: (2018)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla L, et al.
Publicado: (2019)

Psoriasis: Targets and Therapy
Publicado: (2012)

Oyster-shaped hyperkeratotic plaques on the penis
por: Engin Sezer, et al.
Publicado: (2015)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca M, et al.
Publicado: (2021)

Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
por: Anani HAA, et al.
Publicado: (2020)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi A, et al.
Publicado: (2019)

Current knowledge on psoriasis and autoimmune diseases
por: Ayala-Fontánez N, et al.
Publicado: (2016)

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
por: Francisco J. Navarro-Triviño, et al.
Publicado: (2021)

Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
por: Teklu M, et al.
Publicado: (2021)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig MB, et al.
Publicado: (2021)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
por: Luis Puig, et al.
Publicado: (2021)

Serum TSLP is a potential biomarker of psoriasis vulgaris activity
por: El-Ghareeb MI, et al.
Publicado: (2019)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016)

Acrodermatitis continua of Hallopeau: clinical perspectives
por: Smith MP, et al.
Publicado: (2019)